Literature DB >> 29211670

Long-Term Effects of G-CSF Therapy in Cyclic Neutropenia.

David C Dale1, AudreyAnna Bolyard1, Tracy Marrero1, Vahagn Makaryan1, MaryAnn Bonilla2, Daniel C Link3, Peter Newburger4, Akiko Shimamura5, Laurence A Boxer6, Charles Spiekerman7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29211670      PMCID： PMC5777346          DOI： 10.1056/NEJMc1709258

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Treatment of cyclic neutropenia with granulocyte colony-stimulating factor.

Authors:  W P Hammond; T H Price; L M Souza; D C Dale
Journal:  N Engl J Med       Date:  1989-05-18       Impact factor: 91.245

2.  Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis.

Authors:  M Horwitz; K F Benson; R E Person; A G Aprikyan; D C Dale
Journal:  Nat Genet       Date:  1999-12       Impact factor: 38.330

3.  A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia.

Authors:  D C Dale; M A Bonilla; M W Davis; A M Nakanishi; W P Hammond; J Kurtzberg; W Wang; A Jakubowski; E Winton; P Lalezari
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

Review 4.  Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry.

Authors:  David C Dale; Tammy E Cottle; Carol J Fier; Audrey Anna Bolyard; Mary Ann Bonilla; Laurence A Boxer; Bonnie Cham; Melvin H Freedman; George Kannourakis; Sally E Kinsey; Robert Davis; Debra Scarlata; Beate Schwinzer; Cornelia Zeidler; Karl Welte
Journal:  Am J Hematol       Date:  2003-02       Impact factor: 10.047
  4 in total
  12 in total

1.  Registries for study of nonmalignant hematological diseases: the example of the Severe Chronic Neutropenia International Registry.

Authors:  David C Dale; Audrey Anna Bolyard; Laurie A Steele; Cornelia Zeidler; Karl Welte
Journal:  Curr Opin Hematol       Date:  2020-01       Impact factor: 3.284

Review 2.  Maximizing Breast Cancer Therapy with Awareness of Potential Treatment-Related Blood Disorders.

Authors:  Henry G Kaplan; Gregory S Calip; Judith A Malmgren
Journal:  Oncologist       Date:  2020-02-19

3.  Radiation Nephropathy in a Nonhuman Primate Model of Partial-body Irradiation with Minimal Bone Marrow Sparing-Part 1: Acute and Chronic Kidney Injury and the Influence of Neupogen.

Authors:  Eric P Cohen; Kim G Hankey; Ann M Farese; George A Parker; Jace W Jones; Maureen A Kane; Alexander Bennett; Thomas J MacVittie
Journal:  Health Phys       Date:  2019-03       Impact factor: 1.316

4.  Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor.

Authors:  David C Dale; Audrey Anna Bolyard; Tracy Marrero; Merideth L Kelley; Vahagn Makaryan; Emily Tran; Jamie Leung; Laurence A Boxer; Priya S Kishnani; Stephanie Austin; Corbinian Wanner; Iris A Ferrecchia; Dina Khalaf; Dawn Maze; Joanne Kurtzberg; Cornelia Zeidler; Karl Welte; David A Weinstein
Journal:  Curr Opin Hematol       Date:  2019-01       Impact factor: 3.284

Review 5.  Disease Presentation, Treatment Options, and Outcomes for Myeloid Immunodeficiencies.

Authors:  Elizabeth M Kang
Journal:  Curr Allergy Asthma Rep       Date:  2021-03-05       Impact factor: 4.806

6.  Myelodysplastic syndrome and acute myeloid leukemia after receipt of granulocyte colony-stimulating factors in older patients with non-Hodgkin lymphoma.

Authors:  Gregory S Calip; Kellyn M Moran; Karen I Sweiss; Pritesh R Patel; Zhaoju Wu; Sruthi Adimadhyam; Todd A Lee; Naomi Y Ko; John G Quigley; Brian C-H Chiu
Journal:  Cancer       Date:  2018-12-12       Impact factor: 6.921

7.  Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor.

Authors:  David C Dale; Audrey Anna Bolyard; James A Shannon; James A Connelly; Daniel C Link; Mary Ann Bonilla; Peter E Newburger
Journal:  Blood Adv       Date:  2022-07-12

8.  Biomarker Supervised G-CSF (Filgrastim) Response in ALS Patients.

Authors:  Siw Johannesen; Bettina Budeus; Sebastian Peters; Sabine Iberl; Anne-Louise Meyer; Tina Kammermaier; Eva Wirkert; Tim-Henrik Bruun; Verena C Samara; Wilhelm Schulte-Mattler; Wolfgang Herr; Armin Schneider; Jochen Grassinger; Ulrich Bogdahn
Journal:  Front Neurol       Date:  2018-11-26       Impact factor: 4.003

9.  G-CSF shifts erythropoiesis from bone marrow into spleen in the setting of systemic inflammation.

Authors:  Weiqiang Jing; Xing Guo; Fei Qin; Yue Li; Ganyu Wang; Yuxuan Bi; Xing Jin; Lihui Han; Xiaoyuan Dong; Yunxue Zhao
Journal:  Life Sci Alliance       Date:  2020-11-24

Review 10.  Assessment of Congenital Neutropenia in Children: Common Clinical Sceneries and Clues for Management.

Authors:  Ilaria Lazzareschi; Elena Rossi; Antonietta Curatola; Giovanna Capozio; Luca Benacquista; Ludovica Iezzi; Donato Rigante
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-01-01       Impact factor: 2.576
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.